Lincoln Pharmaceuticals Ltd (LINCOLN)

📊 Quarterly Results (₹ Cr)

Revenue has shown a clear upward trend over the past four quarters, rising from Rs. 154 crore in June 2025 to Rs. 177 crore by June 2026, indicating sustained demand and successful execution of growth initiatives. Operating margins have remained stable around 13%, while net profit growth has outpaced revenue expansion, signaling effective cost management and margin accretion. EPS has also improved significantly, climbing from Rs. 13.81 in June 2025 to Rs. 18.09 in June 2026, reflecting both profitability gains and stable share count. This trajectory aligns with management's narrative of scaling operations without compromising efficiency, particularly evident in the consistent EBITDA growth of 32.29% YoY in the latest quarter.

🔮 Management Outlook & What's Next

Management expressed confidence in future growth, targeting Rs. 1,000 crore revenue within three years with annual growth of 15-18%, driven by expanding international presence across 90 countries. The board's recommendation of an 18% dividend for FY25-26, subject to AGM approval, underscores a commitment to returning value to shareholders while maintaining financial flexibility. Management also emphasized the company's net-debt free status and the reaffirmation of CRISIL's 'A/Stable' rating as validation of its financial discipline and strategic direction.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet reflects a strong financial position with zero net debt and growing equity reserves, which have increased from Rs. 652 crore to Rs. 738 crore over the past year. Total assets have expanded steadily, rising from Rs. 797 crore to Rs. 890 crore, indicating successful asset utilization and reinvestment of earnings. The absence of borrowings and consistent cash generation support the company's growth ambitions and dividend commitments without leverage risk.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Institutional investor interest has shown a gradual increase, with FII holdings rising from 4.6% in Q1FY27 to 5.19% in Q4FY26, suggesting growing confidence among foreign investors. Promoter holding remains stable at 49.78%, indicating alignment with long-term value creation. The number of public shareholders has slightly declined, but this may reflect consolidation rather than erosion of interest. Overall, the shareholding pattern shows no signs of dilution or activist pressure, with stable promoter control and incremental institutional accumulation.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Overreliance on international markets exposes the company to geopolitical, regulatory, and currency risks as it expands to 90 countries. 2. The subsidiary LLP remains operationally inactive, which may limit consolidation benefits or raise questions about structural efficiency despite current clarification. 3. Despite strong growth, margins have plateaued around 13% OPM, suggesting potential pricing pressure or input cost volatility that could challenge future profitability expansion without operational upgrades.

📋 Recent Filings

• 🔴 Announcement2026-09-24Lincoln Pharmaceuticals announced the appointment of Pradeep Kumar Yadav as Senior General Manager-Quality Assurance effective September 24, 2026, des…
• 🔴 Announcement2026-09-24Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager- QA (Head QA), effective September 24, 2026, after close of bu…
• Announcement2026-09-23Lincoln Pharmaceuticals has announced that its trading window will close on October 1, 2026, and remain closed for 48 hours after the board approves t…
• 🔴 annual report2026-09-05Lincoln Pharmaceuticals reported FY2025-26 revenue of **₹671.03 crores**, EBITDA of **[amount context mismatch] crores**, and net profit of **[amount …
• 🟡 Board Meeting2026-09-05Lincoln Pharmaceuticals announced its 32nd Annual General Meeting will be held on September 30, 2026 at 11:00 a.m. IST via video conferencing. Shareho…
• 🔴 annual report2026-09-05Lincoln Pharmaceuticals informed shareholders that letters with web links to access the FY2025-26 Annual Report are being sent to those without regist…
• 🟡 Board Meeting2026-08-29Lincoln Pharmaceuticals announced a final dividend of 18% (₹1.80 per share) payable after approval at its September 30, 2026 AGM, with record date set…
• 🟡 Board Meeting2026-08-29Lincoln Pharmaceuticals announced its 32nd Annual General Meeting on September 30, 2026, to approve an 18% final dividend of ₹1.80 per share, triggeri…
• 🟡 Board Meeting2026-08-13Lincoln Pharmaceuticals announced its Q1 FY27 consolidated financial results on August 13, 2026, showing a 30.90% year-on-year increase in net profit …
• Financial Results2026-06-24Lincoln Pharmaceuticals announced that its trading window will close on July 1, 2026, and remain closed until 48 hours after the unaudited financial r…

🧠 Analyst's Read

Lincoln Pharmaceuticals demonstrates consistent financial momentum with healthy profitability, disciplined capital structure, and a clear growth roadmap, but investors should monitor execution risks tied to global expansion and margin sustainability. The upcoming AGM and dividend approval will be key catalysts, while quarterly performance trends suggest management is on track with its stated objectives.

Based on filing content and financial data. Not a recommendation.